Agreement Preamble Sample Clauses

Agreement Preamble. Aggregate Consideration Section 1.6(c) Aggregate Consideration Per Share Section 1.6(c) beneficial owner Section 8.4(b) Book-Entry Shares Section 1.10(b) business day Section 8.4(c) Canadian Company Sale Section 6.2(d) Canadian Plan Section 2.12(a) Cash Designated Shares Section 1.9(e)(ii)(B) Cash Election Shares Section 1.9(b) Certificate of Merger Section 1.2 Certificates Section 1.10(b) Change in the Company Recommendation Section 5.3(b) Closing Section 1.2 Closing Date Section 1.2 Code Recitals Company Preamble Company 401(k) Plan Section 2.12(a) Company Benefit Plans Section 2.12(f) Company Board of Directors Section 2.4(d) Company Common Stock Recitals Company Employees Section 2.18 Company Employee Benefit Plans Section 2.12(c) Company ERISA affiliate Section 2.12(a) Company Financial Advisors Section 2.4(d) Company Material Adverse Effect Section 2.1 Company Material Contracts Section 2.21(a) Company Material Subsidiaries Section 2.1 Company Pension Plan Section 2.12(a) Company Permits Section 2.6(c) Company Preferred Stock Section 2.3 Company Recommendation Section 5.1(e) Company Reserve Reports Section 2.14(c) Company Rights Plan Section 2.3 Company Schedule Article III Company SEC Reports Section 2.7(a) Company Stockholder Approval Section 5.1(e) Company Termination Fee Section 7.3(a) Confidentiality Agreement Section 5.2(b) control Section 8.4(d) controlled by Section 8.4(d) Debt Financing Section 5.10(a) Deemed Shares Outstanding Section 1.6(c) Delaware Law Recitals Dissenting Share Section 1.8(a) Effective Time Section 1.2 Election Deadline Section 1.9(b) Election Form Section 1.9(a) Election Form Record Date Section 1.9(a) Employment Agreement Section 4.1(f) Environmental Laws Section 2.17(a) ERISA Section 2.12(a) Exchange Act Section 2.5(b) Exchange Agent Section 1.10(a) Exchange Fund Section 1.10(a) Exchange Ratio Section 1.6(c) Expenses Section 7.3(d) Final Parent Stock Price Section 1.6(c) Funds Section 5.10(a) GAAP Section 2.1 good and defensible title Section 2.14(e) governmental authority Section 8.4(e) Hazardous Substance Section 2.17(a) HSR Act Section 2.5(b) Hydrocarbons Section 2.14(b) Indemnified Parties Section 5.4(b) Intellectual Property Section 2.20 IRS Section 2.12(a) Letter Section 3.23 Mailing Date Section 1.9(a) Merger Recitals Merger Consideration Section 1.6(a) Merger Sub Preamble NCOC 401(k) Section 2.12(a) NCOC MP Plan Section 2.12(a) Non-Election Shares Section 1.9(b) Notice of Intended Change in the Company Recommen...

Agreement Preamble. Alliance Manager 3.1 Anti-Corruption Laws 12.7(a)(i) Audited Party 9.10(b)(i) Auditing Party 9.10(b)(i) Breach Notification 15.2(b)(i) BTC Data Package 1.65 Claims 13.1 Clinical Supply Agreement 7.3(b) CMO 7.2 Commercial Supply Agreement 7.3(c) Commercialization Milestone Event 9.4 Commercialization Milestone Payment 9.4 Commitments Log 4.1 Confidentiality Agreement 17.11 Continuing Technology Transfer 4.1 Disclosing Party 1.21 Dispute 17.5(a) DMF 6.3 DOJ 16.2(a) Excluded Claim 1.1(e) Execution Date Preamble Executive Officers 17.5(a) Executive Sponsors 3.2(f) Existing Regulatory Materials 12.2(s) Ex-Territory Infringement 14.4(a) First BLA 6.2(b) FTC 16.2(b) Global Brand Elements 8.3(c) HSR Filing 16.1(a) ICH Guidelines 1.37 Indemnified Party 13.3 Indemnifying Party 13.3 Initial Technology Transfer 4.1 Jazz Preamble Jazz Collaboration IP 14.1(a) Jazz Collaboration Patent Rights 14.3(d) Jazz Competing Product 1.1(a) Jazz Indemnitee(s) 13.2 Jazz Publication 11.1(b) Joint Collaboration IP 14.1(a) Joint Patent Rights 14.1(d) JSC 3.2(a) License 2.1(b) Losses 13.1 Manufacturing Technology Transfer 7.2 Manufacturing Technology Transfer Plan 7.2 Manufacturing Transition Date 7.3(a) Manufacturing Working Group 3.2(g)(ii) Negotiation Period 2.8 Notice of Dispute 17.5(a) Offered Rights 2.8 Parties Preamble Party Preamble Patent Liaison 14.2 [*** ***] Post-Approval Commitments 6.7(b) PPQ 7.4(a) Product Infringement 14.4(a) Product Marks 14.9(a) Public Official 12.7(d) Publication 11.1(c) Quality Technical Agreement 7.3(d) Receiving Party 1.21 Regulatory Milestone Event 9.3 Regulatory Milestone Payment 9.3 Regulatory Working Group 3.2(g)(iii) Request Period 2.8 Review Period 11.1(b) Royalty Floor 9.6(c)(iii) Royalty Term 9.6(b) Safety Working Group 3.2(g)(iv) SDEA Agreement 6.4 SEC 11.3(c) Second Payment 9.1(b) Second Payment Due Date 9.1(b) Second Request 16.1(b) Securities Regulators 11.3(c) Technology Transfer 4.1 Term 15.1 Territory Development Plan 5.4 Upfront Payment 9.1(a) Western Europe 1.60 Working Group 3.2(g)(i) [*** ***] Zanidatamab 1.50 Zymeworks Preamble Zymeworks Collaboration IP 14.1(a) Zymeworks Competing Product 1.1(b) Zymeworks Development Plan 5.2(a) Zymeworks Domain Names 14.9(b)(v) Zymeworks Indemnitee(s) 13.1 Zymeworks Manufacturing IP 7.2 Zymeworks Platform Patents 1.79 Zymeworks Publication 11.1(c)

Agreement Preamble. Bankruptcy and Equity Exceptions 2.2(a) Board of Directors (or Board) 2.2(b) Company Preamble Conversion Shares 2.2(a) Governmental Entity 2.3(a) Investor Preamble Loan 1.1 Loan Date 1.2 Loan Documents 2.2(a) September 2016 Convertible Note 1.1 Options 2.4(c) Preferred Stock 2.4(a) Securities 2.5(b) Securities Act 2.5(b)

Agreement Preamble. This Agreement is negotiated pursuant to the Ohio Public Employee Collective Bargaining Act (Chapter 4117 of the Ohio Revised Code). The parties agree that there is no waiver of any of the rights granted under the Act. Where a provision of this Agreement conflicts with state law, this Agreement shall prevail. The Cleveland Metropolitan School District and the Cleveland Teachers Union jointly affirm their commitment to providing a quality education for all of Cleveland’s children. The term children includes students in both elementary and secondary grades. The Cleveland Metropolitan School District and the Cleveland Teachers Union mutually recognize that a safe and secure learning and working environment is essential to the achievement of the educational goals and objectives of the District. Accordingly, the District reaffirms its commitment to provide for the safety of students, employees, parents, and all other school community stakeholders. All stakeholders in the Cleveland Metropolitan School District shall treat one another with professionalism and respect, recognizing that the ultimate success of the District in educating Cleveland’s children requires the efforts of each and every individual.

Agreement Preamble. Applicable Fraction Section 1.36(i)-(v) Breach Issue Recitals Commercialization Agreement Section 3.2(a) Confidential Information Section 6.2 Courts Section 11.2 Deciding Bankers Section 3.2(b) Effective Date Preamble Effective Time Section 9.5(b) First Sales Date Estimate Section 3.3 GK Statement Recitals Glucokinase Activator Section 1.11 Indemnified Party Section 8.3(a) Indemnifying Party Section 8.3(a) Infringement Claim Section 5.5 Invalidity Claim Section 5.4 Novo Preamble Novo Parties Section 8.2 Paragraph IV Claim Section 5.3(a) Partner Deadline Section 3.2(a) Product Liability Section 8.1(c)(ii)(A) Prosecution Section 5.2(a) Released Group Section 10.1 Releasing Group Section 10.1 Releasor Section 10.1 Reverting Rights Section 2.1(a) Royalty Term Section 4.2(c) Stand-by License Agreement Section 9.5(b) Term Section 9.1 Third-Party Claims Section 8.1(c) TransTech Preamble TransTech Parties Section 8.1 Umbrella Agreement Recitals

Agreement Preamble. Aggregate Purchase Price 1.2 Amended Articles 1.1 Acquired Shares 1.2 Balance Sheet Date 2.7(a) Bankruptcy and Equity Exceptions 2.2 Closing 1.5 Closing Date 1.5 Code 2.10 Common Stock 2.4(a) Company Preamble Company Assets 2.11 Conversion Shares 2.5 Disclosure Schedule Section 2 Entity Investor 3.1 Equity Incentive Plan 2.4(d) Existing Stockholders Preamble FCPA 2.24 Financial Institution 3.11(a) Financial Statements 2.7(a) Founders Preamble GAAP 2.7(b) Governmental Entity 2.3(a) Investment Transaction Recitals Investor[s] Preamble Non-Competition Agreement 2.18(c) OFAC 3.11(a) Offering Memorandum 2.23(a) Options 2.4(e) Outstanding Plan Options 2.4(d) Per Share Price 1.2 PIIA Agreement 2.18(c) Preferred Stock 2.4(a) Purchaser Party 3.11(a) Registration Rights Agreement Recitals Securities 3.4 Securities Act 2.3(b) Series A Preferred Stock 2.4(a) Series B Preferred Stock Recitals Small Business Act 2.27 Specially Designated Nationals and Blocked Persons 3.11(a) State Secretary 5.7 Stockholders Agreement Recitals U.S. Person 3.11(a)

Agreement Preamble. Ancillary Agreements 1.1

Agreement Preamble. Alliance Manager 3.1 Assumed Development Activities 4.3.1 Bankruptcy Code 12.8 Biohaven Preamble Biohaven BMS Non-Compete Term 5.7.1(b) Biohaven HoldCo Preamble Biohaven Ireland Preamble Biohaven Patent Stepdown 6.5.2 Biohaven Patent Stepdown Amount 6.6.4 BioShin Preamble BioShin Additional Third Party License 14.5.1 BioShin Patent Stepdown 14.4.2 BioShin Royalty Term 14.4.1 BioShin Territory Biohaven Patent Stepdown Amount 14.5.4 BMS Definition of “BMS Agreement” BMS Consent Letter Recitals BMS Sublicense Recitals Chosen Court 13.3 CMC Strategy 3.3.2(c) Commercialization Plan 5.2.1 Competitive Activities 5.7.2(d) CRLR Definition of “CGRP Receptor” Development Activities Cure Period 4.3.1 Development Plan 4.2.1 Disclosing Party 8.1 Discontinuation Notice 4.3.1 Distribution Agreement 5.5.3(c) Educational Materials 5.4 Execution Date Preamble Global Safety Database 4.8 Indemnification Claim 10.3 Indemnitee 10.3 Indemnitor 10.3 Independent Affiliate 5.7.2(d) Initial Commercialization Plan 5.2.1 Initial Development Plan 4.2.1 Inventions 7.1.1 JCC 3.4.1 JDMRC 3.2.1 JMC 3.3.1 Joint Inventions 7.1.2 Joint Patent Rights 7.3 Licensor Preamble Licensor Company Marks 7.6.3 Licensor Product Marks 7.6.3 Losses and Claims 10.1 Marketing Materials 5.4 material adverse condition or event 4.7 Modified Clause 13.11 NICE Appraisal 6.3 Notice of Dispute 13.2.1 Notice Period 12.3.2 OTC Nurtec 6.8 Party Preamble Party Vote 3.7 Pfizer Preamble Pfizer BMS Non-Compete Term 5.7.1 Pfizer Development Activities 4.2.3 Pfizer Product Marks 7.6.2 Prevention Indication Definition of “Initial Indications” Quality Agreements 5.5.3(b) RAMP 1 Definition of “CGRP Receptor” RCP Definition of “CGRP Receptor” Receiving Party 8.1 Regulatory Know-How Transfer 4.6.2 Related Party Definition of “Net Sales” Required Post-Approval Development Activities 4.2.2 Reversion Products 12.6.2 Reversion Regulatory Materials 12.6.10 rimegepant Definition of “Licensed Compound” Royalty Term 6.5.1 Safety Data Exchange Agreement or SDEA 4.8 Senior Executives 3.8.1 [***] [***] Sublicensee 2.2 Subscription Agreement Recitals Supply Agreement 5.5.1(a) Supply Plan 5.5.2 Term 12.1 Termination Notice 12.3.2 Three-way Quality Agreement 5.5.3(b) Title 11 12.8 Trademark License Agreement 7.6.3 Triggering Event 5.7.1(b) Two-way Quality Agreement 5.5.3(a) VAT 6.15.2 zavegepant Definition of “Licensed Compound”

Agreement Preamble. Assumed Liabilities 1.5 Assumption Agreement 2.1(b) Business Day 12.17 Buyer Preamble Buyer Receivables 10.7(a) Buyer Indemnified Parties 11.2 ▇▇▇▇▇’s Representative 12.26 Cash 1.3(a) CERCLA 3.15 Certificate of Need 3.7 Clinic or Clinics Recitals Closing 2 Closing Amount 1.9(c) Closing Date 2 Closing Documents 3.27 Closing Month End Balance Sheet 1.8(b) COBRA 1.4 Code 3.13(a) Contracts 1.2(h) DCH 3.7 Deductible 11.6(a) Designated Cost Reports 1.5(b) Employee Benefits Plans 3.13(a) Environmental Laws 3.15 ERISA 3.13(a) ERISA Affiliate 3.13(c) Estimated Purchase Price 1.8(b) Excluded Assets 1.3 Financial Information 3.4 Financial Information Date 3.4(b) Fiscal Year 3.4(a) Forward Looking Materials 3.30 Fundamental Representations 11.5 GAAP 3.4 Government Entity 3.9 HIPAA 3.9 HITECH Act 3.9 Indemnified Party 11.3 Indemnifying Party 11.3 Insolvency Event(s) 7.6 Inventory 12.17 Knowledge of Buyer 4 Knowledge of Seller 3 Lien or Liens 3.12 Loss or Losses 11.1 Material Adverse Effect 12.17 MOB or MOBs Recitals Monthly Statements 5.5 Permits 1.2(j) Permitted Encumbrances 3.11 Post-Closing Adjustment 1.9(a) Provider Agreements 1.2(h) Purchase Price 1.8 RCRA 3.15 Real Property 1.2(a) Representatives 12.26 Responsible Officers 3 Retained Employees 10.9(a) Retained Liabilities 1.4 SEC 3.5(h) SNF Recitals Securities Act 4.6 Seller Preamble Seller Counsel 12.19 Seller Indemnified Parties 11.1 Seller’s Agent 3.30 Seller’s Knowledge 3 Seller’s Representative 12.26 September 30 Financial Information 1.9(a) Shares Recitals Southern Recitals Straddle Patients 10.7(a) Surveys 5.10 Target Amount 1.9(c) Territory 9.1 Title Company 5.9 Title Policy 5.9 Trace Regional Recitals Trace Regional Assets 1.2 Trace Regional Forms 10.10 WARN Act 3.18(c) Working Capital Payables 1.9(d) Working Capital Receivables 1.9(d) - ix - This Stock Purchase Agreement (the “Agreement”) is made and entered into as of November 10, 2023, by and between Crown Healthcare Investments, LLC, a Georgia limited liability company (“Seller”), and Progressive Health Group, LLC (“Buyer”) a Mississippi limited liability company.